Document is current
Any future updates will be listed below
-
Authors
Gaetani, Lorenzo https://orcid.org/0000-0003-3967-8954
Bellomo, Giovanni https://orcid.org/0000-0003-0456-5650
Chiasserini, Davide https://orcid.org/0000-0002-1169-3258
De Rocker, Charlotte
Goossens, Julie https://orcid.org/0000-0001-5336-1238
Paolini Paoletti, Federico https://orcid.org/0000-0001-9623-1900
Vanmechelen, Eugeen https://orcid.org/0000-0002-9466-5366
Parnetti, Lucilla https://orcid.org/0000-0001-5722-3967
-
Funding
Funding for this research was provided by:
Associazione Italiana Ricerca Alzheimer (AGYR 2023)
NextGenerationEU (PNRR‐MAD‐2022‐12376035)
Parkinson's Foundation (PF‐PRF‐934916)
- License Information
-
More Information
Article History
Received: 26 February 2025
Accepted: 12 May 2025
First Online: 22 May 2025
Declarations
:
: The study was approved by the local Ethics Committee (Comitato Etico Aziende Sanitarie Regione Umbria 19369/AV and 20942/21/OV). All the patients provided informed consent to participate in the study.
: Not applicable.
: LG has participated in advisory boards for and received writing or speaker honoraria and travel grants from Almirall, Biogen, Eisai, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. GB received honoraria from Fujirebio and completed paid consultancies for Parkinson’s Foundation. He received travel/educational grants from Fujirebio and Alzheimer’s Association. DC has nothing to disclose. CDR and JG are employee at ADx NeuroSciences NV, Ghent, Belgium. FPP has nothing to disclose. EV is co-founder of ADx NeuroSciences NV, Ghent, Belgium. LP served as Member of Advisory Boards for Fujirebio, IBL, Roche, and Merck.
